# Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)

> **NCT00758225** · PHASE2 · COMPLETED · sponsor: **Santhera Pharmaceuticals** · enrollment: 21 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Idebenone

## Key facts

- **NCT ID:** NCT00758225
- **Lead sponsor:** Santhera Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2011-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00758225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00758225, "Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00758225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*